Related Experiment Video
Updated: Jun 19, 2026
08:43
Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
Vasculotropic effects of calcimimetics.
Nadezda Koleganova1, Grzegorz Piecha, Eberhard Ritz
1Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany. nad_ko@gmx.de
Current Opinion in Nephrology and Hypertension
|October 10, 2009
Summary
Calcimimetics show promise in treating cardiovascular complications in chronic kidney disease (CKD). These drugs may improve vascular health and reduce mortality, independent of their effects on mineral levels.
Area of Science:
- Nephrology
- Cardiology
- Pharmacology
Background:
- Cardiovascular disease is the leading cause of mortality in chronic kidney disease (CKD).
- Secondary hyperparathyroidism, hyperphosphatemia, and hypercalcemia contribute to cardiovascular complications in CKD.
- Current treatments for high-risk CKD patients remain suboptimal.
Purpose of the Study:
- To evaluate the potential of calcimimetics as cardiovascular interventions in CKD.
- To explore the pleiotropic effects of calcimimetics on cardiovascular health.
Main Methods:
- Review of experimental studies on calcimimetics in CKD models.
- Analysis of clinical observations and retrospective data regarding calcimimetic use in CKD patients.
Main Results:
- Calcimimetics demonstrated beneficial effects on vascular abnormalities in experimental CKD.
- These effects appear partially independent of mineral and parathyroid hormone levels.
- Observed benefits include improved vascular calcification, reduced atherogenesis, and enhanced myocardial capillarization, alongside hypotensive and renoprotective actions.
Conclusions:
- Experimental data suggest calcimimetics may offer cardiovascular benefits in CKD.
- Retrospective human data hint at similar benefits, though prospective trials are needed.
- Further clinical trials are warranted to confirm hard cardiovascular endpoints.
Related Concept Videos
00:51Synthesis and Functions of Calcitonin
Calcitonin, a vital polypeptide hormone, regulates calcium levels within body fluids. It is released by the parafollicular cells, also known as C cells, situated in the follicular epithelium of the thyroid gland. Calcitonin responds to fluctuations in blood calcium levels and the influence of gastrointestinal hormones like gastrin and cholecystokinin.
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
01:17Hormones and Bone Tissue
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:23Antihypertensive Drugs: Vasodilators
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
01:16Calmodulin-dependent Signaling
Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...